Compare Tilray Brands Inc (TLRY) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tilray Brands Inc vs Verisign, Inc. — how do they compare? Tilray Brands Inc trades at $4.21 (market cap $577.15M), while Verisign, Inc. trades at $287 (market cap $25.94B). The key difference: Verisign, Inc. is far larger — about 44.9× Tilray Brands Inc's market cap, and Verisign, Inc. pays a 1.13% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| TLRY | VRSN | |
|---|---|---|
Market Cap | $577.15M | $25.94B |
Sector | Health | Technology |
52-Week High | $21.00 | $310.00 |
52-Week Low | $3.88 | $211.49 |
Enterprise Value | $744.29M | $27.25B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLRY trades at $4.30, down 4.44% with a bearish technical outlook. The company reported record fiscal 2026 revenue of $915M but continues to post significant losses with a -13.27% net margin. Recent news highlights expansion in spirits distribution and medical cannabis production, though regulatory uncertainty weighs on sentiment. The stock trades below book value with a P/S of 0.51 and P/B of 0.36, suggesting potential undervaluation despite profitability challenges.
TLRY presents a high-risk opportunity with mixed signals. The discounted valuation and expanding beverage/alcohol business offer upside potential, but persistent losses, negative cash flow, and cannabis regulatory delays create substantial headwinds. Analyst consensus leans cautious with 65% hold ratings, reflecting the stock's speculative nature amid ongoing operational challenges.
VeriSign (VRSN) trades at $282.20, down 3.38% on the day, with a bearish technical signal despite strong institutional buying interest. The company maintains exceptional profitability with 49.77% net margins and consistent revenue growth, though recent earnings have been mixed with two misses in the last four quarters. A major antitrust lawsuit filed in September 2026 poses significant regulatory risk, while analyst consensus remains bullish with a $328.50 price target representing 16% upside potential.
The stock presents a compelling value proposition given its strong cash flow generation and dominant market position in domain registry services, but faces headwinds from legal challenges and competitive pressures. Current valuation at 30.64 P/E appears reasonable for the quality of earnings, though the negative shareholder equity position warrants monitoring of debt levels. Upside potential exists if the company successfully navigates regulatory challenges and maintains its pricing power.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
